SAREUM HOLDINGS PLC - Unaudited financial results for the six months ended 31 December 2025 скачать в хорошем качестве

SAREUM HOLDINGS PLC - Unaudited financial results for the six months ended 31 December 2025

To be informed of all SAREUM HOLDINGS PLC's upcoming presentations, register at Investor Meet Company: https://www.investormeetcompany.com/s... 0:00 Introduction 1:20 Company Overview 5:13 TYK2 / JAK1 inhibitor programmes 22:00 Chk1 - SRA737 25:40 Preliminary Financial Results 28:37 Pipeline status and priorities 31:11 Q&A Sareum Holdings PLC (SAR:AIM) provided an investor update alongside its interim financial results for the six months ended 31 December, outlining company performance, pipeline progress, and strategic priorities. The biotechnology company continues to advance its lead programme SDC 1801, a selective TYK2 JAK1 inhibitor targeting autoimmune diseases such as psoriasis, following positive Phase 1 data demonstrating strong safety, tolerability, and pharmacokinetics supporting once daily dosing. The Phase 2 enabling toxicology programme has restarted with a new global CRO and dosing is underway, with completion expected mid 2026 and a full regulatory package targeted by year end. Sareum also confirmed progress in formulation optimisation and GMP manufacturing to support future clinical trials. The company is preparing SDC 1802, a related TYK2 JAK1 inhibitor for oncology applications including blood cancers, for potential licensing as it seeks a specialist development partner. Meanwhile SRA 737, a clinical stage CHK1 inhibitor with promising combination therapy potential in oncology, continues to be positioned for partnering opportunities following improved licensing economics and extended intellectual property protection to at least 2041. Sareum is also expanding its pipeline through a neuroscience collaboration with Receptor AI focused on brain penetrant kinase inhibitors targeting neuroinflammatory diseases such as Alzheimer’s and Parkinson’s. Financial results show controlled operating expenses and cash resources of £2.5 million as the company maintains its strategy of advancing assets to value inflection points before securing pharmaceutical partnerships. Management highlighted multiple upcoming catalysts across the portfolio and reiterated its growth strategy focused on licensing, collaboration, and maximizing shareholder value through the development of differentiated kinase inhibitor therapies.